Csizmar CM, Gurney M, Kanagal-Shamanna R, Chien K, Hammond D, Lasho TL, Finke CM, Dean C, Natu A, Mangaonkar AA, Al-Kali A, Gangat N, Tefferi A, Alkhateeb H, Garcia-Manero G, Komrokji RS, Ali NA, Padron E, Montalban-Bravo G, Patnaik MM. <i>ASXL1/TET2</i> genotype-based risk stratification outperforms <i>ASXL1</i> mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia. haematol [Internet]. 2024Oct.1 [cited 2024Nov.23];109(10):3419-25. Available from: https://haematologica.org/article/view/haematol.2024.285410